Bardoxolone methyl(NSC 713200; RTA 402; CDDO Methyl ester) is the lead molecule in Reata's portfolio of Antioxidant Inflammation Modulators (AIMs). The AIMs are potent inducers of the transcription factor Nrf2, an important biological target that controls the production of many of the body's antioxidant and detoxification enzymes. Because oxidative stress and inflammation occur throughout the course of chronic kidney disease (CKD) and are known to contribute to loss of kidney function, agents that activate the Nrf2 pathway in patients with CKD may provide a novel method for preserving or improving kidney function. Bardoxolone methyl(NSC 713200; RTA 402; CDDO Methyl ester) is currently being investigated as a potential oral once-a-day treatment for CKD.
ChemScene can order timely high quality and efficient services of various compounds from mg to kg level for some clients' bioscience research. We are committed to researching and developing reference compounds with high synthesis technology barriers and difficulties. ChemScene also has a tradition of working with scientists to bring new discoveries out of the laboratory and into the commercial arena.
View more >>
United States
China 